Heart Failure Management: SGLT2i and GLP-1 RA Mechanism of Action
09/20/22 • 24 min
CE contact hours are no longer available for the content covered in this podcast episode. Check out the online library at pcna.net for up-to-date CE offerings.
Often prescribed for obesity, SGLT2is and GLP-1 RAs have a role in heart failure management. Learn about their mechanisms of action, and how their use extends beyond weight loss to cardioprotective and renalprotective properties. Guests: Kim Newlin, MSN, ANP, FPCNA, of Sutter Roseville Medical Center in Northern California, and Colleen McIlvennan, PhD, DNP, ANP, FAHA, FHFSA, from the University of Colorado in Denver.
2022 AHA/ACC/HFSA 2022 Guideline for the Managment of HF: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
Pocket Guide: Guidelines for Managing CVD Risk in Patients with Diabetes: https://pcna.net/clinical-resources/provider-tools/diabetes-provider-tools/
HF Pocket Guide: A Guide to Prevention and Management: https://pcna.net/clinical-resources/provider-tools/heart-failure-provider-tools/
New and Emerging Treatments for Heart Failure: HFrEF and HFpEF (CE course): https://pcna.net/online-course/new-and-emerging-treatments-for-heart-failure-hfref-and-hfpef/
SGLT2is in Heart Failure: ncbi.nlm.nih.gov/pmc/articles/PMC8654149/
SGLT2i in HFpEF: multicenter randomized trial: nature.com/articles/s41591-021-01536-x
Empagliflozin in HFpEF: https://www.nejm.org/doi/10.1056/NEJMoa2107038#:~:text=Empagliflozin%20in%20HF%20with%20Preserved%20Ejection%20Fraction&text=Sodium%E2%80%93glucose%20cotransporter%202%20(SGLT2,and%20a%20reduced%20ejection%20fraction.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
CE contact hours are no longer available for the content covered in this podcast episode. Check out the online library at pcna.net for up-to-date CE offerings.
Often prescribed for obesity, SGLT2is and GLP-1 RAs have a role in heart failure management. Learn about their mechanisms of action, and how their use extends beyond weight loss to cardioprotective and renalprotective properties. Guests: Kim Newlin, MSN, ANP, FPCNA, of Sutter Roseville Medical Center in Northern California, and Colleen McIlvennan, PhD, DNP, ANP, FAHA, FHFSA, from the University of Colorado in Denver.
2022 AHA/ACC/HFSA 2022 Guideline for the Managment of HF: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
Pocket Guide: Guidelines for Managing CVD Risk in Patients with Diabetes: https://pcna.net/clinical-resources/provider-tools/diabetes-provider-tools/
HF Pocket Guide: A Guide to Prevention and Management: https://pcna.net/clinical-resources/provider-tools/heart-failure-provider-tools/
New and Emerging Treatments for Heart Failure: HFrEF and HFpEF (CE course): https://pcna.net/online-course/new-and-emerging-treatments-for-heart-failure-hfref-and-hfpef/
SGLT2is in Heart Failure: ncbi.nlm.nih.gov/pmc/articles/PMC8654149/
SGLT2i in HFpEF: multicenter randomized trial: nature.com/articles/s41591-021-01536-x
Empagliflozin in HFpEF: https://www.nejm.org/doi/10.1056/NEJMoa2107038#:~:text=Empagliflozin%20in%20HF%20with%20Preserved%20Ejection%20Fraction&text=Sodium%E2%80%93glucose%20cotransporter%202%20(SGLT2,and%20a%20reduced%20ejection%20fraction.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Previous Episode
AFib Management in Clinical Practice
Atrial fibrillation (AFib) management includes both pharmacologic and non-pharmacologic therapies.Guest Bill Miles, MD, FACC, of the University of Florida, Gainsville, describes how to effectively treat AFib--from asymptomatic younger patients without left ventricular dysfunction to older patients with significantly reduced ejection fraction.
AFib resources for healthcare providers
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Next Episode
Heart Failure Management: Health Equity and Access to Care
CE contact hours are no longer available for the content covered in this podcast episode. Check out the online library at pcna.net for up-to-date CE offerings.
Health equity issues, including access ot medications, significantly impact patients with heart failure. From pharmacy deserts to non-medical switching and beyond, hear strategies to assist patients in getting the medications they need, from nurses Binu Koirala, PhD, MGS, RN, with the Johns Hopkins University School of Nursing in Baltimore, and Kim Newlin, MSN, ANP, FPCNA, of Sutter Roseville Medical Center in Northern California.
Access to Innovative Medicines Provider Tools: https://pcna.net/clinical-resources/provider-tools/access-for-innovative-medicines-provider-tools/
Medicare State Pharmaceutical Assistance Program: medicare.gov/pharmaceutical-assistance-program/#state-programs
Extra Help with Medicare Prescription Drug Care Costss: ssa.gov/benefits/medicare/prescriptionhelp.html
CoverMyMeds: covermymeds.com/main/
Solving Medication Access issues: acc.org/latest-in-cardiology/articles/2020/10/01/01/42/feature-advancing-health-equity-for-heart-failure-patients
Non-Medical Switching: cga.ct.gov/2017/rpt/2017-R-0008.htm#:~:text=%E2%80%9CNon%2Dmedical%20switching%E2%80%9D%20broadly,expensive%20but%20therapeutically%20equivalent%20drug
Health Equity: cdc.gov/chronicdisease/healthequity/index.htm
Understanding Copay Accumulators: https://infusioncenter.org/understanding-copay-accumulators-who-really-benefits/
PACH (Partnership to Advance Cardovascular Health): advancecardiohealth.org/
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/heart-to-heart-nurses-451039/heart-failure-management-sglt2i-and-glp-1-ra-mechanism-of-action-61445614"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to heart failure management: sglt2i and glp-1 ra mechanism of action on goodpods" style="width: 225px" /> </a>
Copy